About Entasis

The Entasis Leadership Team

The team at Entasis combines deep scientific expertise with senior leadership experience in the global pharmaceutical industry. We focus on research excellence in the delivery of the next generation of antibacterials to patients, and on cultivating a great place to work. We are seeking to engage with external partners to fully realize the potential and value of our solid pipeline of candidate medicines.

Manos Perros, PhD | President and Chief Executive Officer
Mike Gutch, PhD | Chief Business Officer and Chief Financial Officer
Robin Isaacs, MD | Chief Medical Officer
John Mueller, PhD | Chief Development Officer
Ruben Tommasi, PhD | Chief Scientific Officer

 

Manos Perros, PhD | President and Chief Executive Officer
Dr. Manos Perros was central to the establishment of Entasis Therapeutics, and led talks with AstraZeneca that resulted in the creation of the new company in 2015.  Manos was Vice President of the Innovative medicines and Early Development unit of and Head of AstraZeneca’s Infection Innovative Medicines organization for more than four years, and also served as Site Head, for AstraZeneca’s Boston R&D research centre and Gatehouse Park BioHub in Waltham, MA. In his role as the Infection Head, Manos was accountable for the Infection delivery from idea to clinical proof-of-concept of a portfolio of programs against serious bacterial infections, respiratory viruses, and neglected infectious diseases (tuberculosis and malaria in particular). Manos was also the executive sponsor for the Global Chemistry Leadership team at AstraZeneca, and led the evolution of the organizational and sourcing model, including the establishment of a strategic partnership with Pharmaron (China). A chemist by training, Manos conducted his PhD work in Belgium, France and Germany, and was Associate in the Biophysics department at Yale from 1993-1995. Prior to joining AstraZeneca, Manos served as Director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as Vice-President and Chief Scientific Officer, Antivirals, at Pfizer. Manos has overseen a wide range of therapeutic areas, but his greatest contributions have been in the field of anti-infectives, where he is a distinguished and widely published scientist, having led research projects against HIV, Hepatitis C, influenza and fungal pathogens. Amongst a number of molecules still in development, Manos is a co-inventor of the first-in-class HIV treatment maraviroc (Celsentri/Selzentry) on which he worked from inception to launch. The medicine earned numerous accolades, including the 2008 Prix Galien USA. For his contributions to the discovery and development of maraviroc, Manos received the PhRMA Discoverer’s Award in 2010.

Michael Gutch, PhD | Chief Business Officer / Chief Financial Officer
Dr. Michael Gutch joined Entasis in April 2017 as Chief Business Officer and Chief Financial Officer. Mike joins Entasis from AstraZeneca’s Corporate Development group where he was an Executive Director and Head of Equities, having responsibility for AstraZeneca’s equity portfolio, mergers and acquisitions, divestments and spin-outs. He led AstraZeneca’s negotiation team in the creation of Entasis Therapeutics and was responsible for its transition to an independent company. Prior to joining AstraZeneca, Mike had experience as both a corporate and private venture capital investor as Managing Director of MedImmune Ventures, a Director with H.I.G. BioVentures, and a Principal with Lilly Ventures, the corporate venture capital arm of Eli Lilly & Company. While at Lilly, Mike was also in the Corporate Financing and Investment Banking group, where he focused on mergers and acquisitions and licensing transactions. Mike earned his PhD in Cellular and Molecular Pathology from the State University of New York at Stony Brook and was a post-doctoral research fellow at both University of California (San Francisco) and the Cold Spring Harbor Laboratories. He earned his MBA in finance from Indiana University. Mike also serves as a Board Director of Albireo Pharma (ALBO).

Robin Isaacs, MD | Chief Medical Officer
Dr. Robin Isaacs joined Entasis in July 2015 as Chief Medical Officer.  Robin is a graduate of the University of Auckland. After completing his medical degree in 1981, he completed clinical training in New Zealand as a general internist with a specialist interest in infectious diseases. From 1987 to 1990, he undertook a clinical and research fellowship in infectious diseases at the University of Texas Southwestern Medical Center in Dallas, Texas. In 1991, he joined the faculty of the University of Mississippi Medical Center in Jackson, Mississippi where he became an Associate Professor of Infectious Diseases. In 1997, he joined the Clinical Research department at MRL. Since January 2009, as vice president and therapeutic area head, he has led either the vaccine and/or infectious disease clinical development groups in Global Clinical Development. Over the past 18 ½ years, he has either worked on directly or supervised the worldwide development, regulatory submission, and approval of many anti-infective, antiviral and vaccine products. Dr. Isaacs has published extensively in the field of infectious diseases, including clinical and basic research studies.

John Mueller, PhD | Chief Development Officer
Dr. John Mueller is Chief Development Officer and a founding leader of the company. He is accountable for all aspects of IND-enabling and early development studies. John served as Senior Project Director at AstraZeneca since 2011. He successful led a global multidisciplinary team to advance ETX0914 (formerly AZD0914), a novel bacterial topoismerase inhibitor for uncomplicated gonorrhea into Phase II studies. He was also responsible for leading an integrated disease area strategy in antibacterial research, led global project teams to the nomination of clinical candidates across a broad range of target mechanisms, provided oversight of the antibacterial portfolio delivery and established a shared alignment of the antibacterial research strategy with partners in commercial and clinical development. John received his PhD in Microbiology and Immunology from the Albany Medical College, and subsequently conducted post-doctoral studies at the Tufts Medical School as a National Institutes of Health (NIH) fellow where he complemented his bacterial genetics research training. His work there led to new insights into novel mechanisms by which bacteria sense and respond to environmental  signals. He has 22 years of experience in the biotech and pharmaceutical industry beginning his career with Alexion Pharmaceuticals. During his tenure at Alexion, he contributed to the biological data package for the filing of Soliris (eculizumab), a first-in-class terminal complement inhibitor for paroxysmal nocturnal hemoglobinuria. He then joined Pfizer in 1997 where he integrated contemporary approaches to antibacterial drug discovery and established and led several novel target discovery projects. He held various positions of increasing responsibility, ultimately serving as Senior Director and Head of Biology for Antibacterials Research. He is co-inventor on six patents and co-author of 43 publications in peer-reviewed scientific journals.

Ruben Tommasi, PhD | Chief Scientific Officer
Dr. Ruben Tommasi is a founding leader of Entasis, and is responsible for providing the scientific direction of the organisation.  Ruben’s leadership as Executive Director, Chemistry, of the Infection Innovative Medicines unit at AstraZeneca, revitalized the portfolio which now forms part of the Entasis portfolio of programs.  Ruben joined AstraZeneca in 2011 to lead Infection Chemistry, after having been at Novartis where he spent 17 years working in the areas of arthritis, inflammation, bone metabolism, hit-to-lead optimization and infection. Ruben received his doctorate degree in Organic Chemistry from the State University of New York, Albany, in 1992, where he developed asymmetric total syntheses of Anthracyclinone natural products, including Daunomycinone, with Professor Frank M. Hauser.  Subsequently, Ruben moved to the University of Colorado at Boulder to work with Professor Gary Molander on Organometallic Chemistry and Natural Product synthesis. Ruben’s main interests include developing heightened understanding of drug permeation into Gram-negative organisms and structure-based drug design.  Ruben is the co-author of 33 papers and co-inventor of 12 patents.